ESRRA and metabolic dysfunction-associated steatohepatitis: Thus, ERRα depletion as well as C29 treatment elevated the mRNA and protein levels of Fbxw7 (Supplementary Fig. 9c–f), further indicating the benefits of ERRα inhibition for NASH treatment.